Collaboration strengthens Ratio’s long-term isotope supply strategy for clinical development and future pipeline growth BOSTON, MA, June 30, 2026 – Ratio Therapeutics Inc. (Ratio), a clinical-stage pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced that it has entered into a strategic supply agreement with PanTera, an innovative producer scaling the supply… Read more

Expanded collaboration adds manufacturing capacity, strengthens redundancy, and supports later-stage development planning for Ratio’s lead FAP-targeted radiotherapeutic candidate BOSTON, May 29, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced an expanded manufacturing collaboration with PharmaLogic Holdings Corp. (PharmaLogic), a leading contract development and manufacturing… Read more

BOSTON, March 12, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Colin Hayward, MBBS, FFPM, as the company’s Chief Medical Officer. Dr. Hayward brings more than 26 years of global experience in the healthcare industry, including leadership in… Read more

BOSTON, MA, December 16, 2025  – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that dosing of the first cohort has been completed in the ATLAS trial, a Phase 1/2 open-label study evaluating the safety, tolerability, and efficacy of the company’s lead… Read more

BOSTON, November 4, 2025  – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced the appointment of Marcel Reichen, Ph.D., MBA, as the company’s Chief Strategy Officer. Dr. Reichen brings over a decade of international experience in the pharmaceutical and radioligand therapy (RLT) industries,… Read more

BOSTON and BELLEVUE, WA, June 20, 2025  – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and TerraPower Isotopes, a subsidiary of TerraPower, a leading nuclear innovation company, today announced they entered into a supply agreement for the medical radioisotope actinium-225 (Ac-225)1. Under the agreement,… Read more